ArriVent BioPharma AVBP
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -8.1x
Near the bottom of its 5-year range · 11th percentile, 5-year average 2.4x
#2750 of 5330 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 99th percentile, 5-year average 1.0x
#4980 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.71 | – | 2.42 | 11% (cheaper than usual) | #2750 of 5330 (1 = cheapest) |
| PE | -3.61 | -3.40 | -8.08 | 99% (pricier than usual) | – |
| PS | 134.58 | 73.51 | 0.98 | 99% (pricier than usual) | #4980 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on AVBP.
Sign in to join the discussion.